Synergetic Effect of Doxorubicin and Avenanthramide C on VDAC2/MTCH1 Mitochondrial Axis in Breast Cancer Cells

Overview

Journal Int J Health Sci (Qassim)

Specialty General Medicine

Date 2025 Mar 6

PMID 40046789

Authors

Ehab M M Ali

Sultan N Sonbul

Eman A Almuhaini

Ayat B Al-Ghafari

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to evaluate the synergistic effects of doxorubicin (DOX) and the natural phenolic alkaloid avenanthramide C (AVC) on enhancing apoptosis in MCF-7 breast cancer (BC) cells, with a specific focus on the expression of mitochondrial proteins voltage-dependent anion channel 2 (VDAC2) and mitochondrial carrier homolog 1 (MTCH1) involved in apoptosis pathways.

Methods: MCF-7 cells were treated with various concentrations of DOX and AVC. The 50% inhibitory concentration (IC) of DOX combined with AVC was evaluated in the MCF-7 cells using an MTT assay, while gene expression levels of , , and were assessed through real-time polymerase chain reaction. Apoptotic rates were measured using flow cytometry.

Results: DOX and AVC combination reduced the IC value by 2.1-fold compared to DOX alone, indicating enhanced cytotoxicity. Co-treatment significantly downregulated expression and increased apoptosis by 76% in cells treated with 3 μM DOX and 160 μM AVC. Gene expression analysis revealed a 4.8-fold increase in MTCH1 and a 15-fold increase in VDAC2 compared to DOX treatment alone.

Conclusion: The DOX-AVC combination demonstrated a potent synergistic effect, enhancing apoptosis in BC cells by modulating mitochondrial pathways. This approach may provide a promising strategy for reducing chemotherapy side effects in BC treatment. Further studies in pre-clinical models are warranted to explore its therapeutic potential.

References

Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y . Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol. 2001; 152(2):237-50. PMC: 2199613. DOI: 10.1083/jcb.152.2.237. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Ali E, Elashkar A, El-Kassas H, Salim E . Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line. Int J Biol Macromol. 2018; 120(Pt A):1170-1180. DOI: 10.1016/j.ijbiomac.2018.08.118. View

Wang J, Wu S . Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. Breast Cancer (Dove Med Press). 2023; 15:721-730. PMC: 10596062. DOI: 10.2147/BCTT.S432526. View

Katoh M . Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45. Int J Oncol. 2002; 20(2):373-7. View

Xie Y, Zhou X, Li J, Yao X, Liu W, Kang F . Identification of a new natural biflavonoids against breast cancer cells induced ferroptosis via the mitochondrial pathway. Bioorg Chem. 2021; 109:104744. DOI: 10.1016/j.bioorg.2021.104744. View

Bellail A, Tse M, Song J, Phuphanich S, Olson J, Sun S . DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med. 2009; 14(6A):1303-17. PMC: 2891654. DOI: 10.1111/j.1582-4934.2009.00777.x. View

Majeed W, Aslam B, Javed I, Khaliq T, Muhammad F, Ali A . Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev. 2014; 15(8):3353-8. DOI: 10.7314/apjcp.2014.15.8.3353. View

Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I . Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023; 12(4). PMC: 9954613. DOI: 10.3390/cells12040659. View

10.

Siegfried J, Kennedy K, Sartorelli A, Tritton T . The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells. J Biol Chem. 1983; 258(1):339-43. View

11.

Carvalho C, Santos R, Cardoso S, Correia S, Oliveira P, Santos M . Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009; 16(25):3267-85. DOI: 10.2174/092986709788803312. View

12.

Stander B, Marais S, Steynberg T, Theron D, Joubert F, Albrecht C . Influence of Sutherlandia frutescens extracts on cell numbers, morphology and gene expression in MCF-7 cells. J Ethnopharmacol. 2007; 112(2):312-8. DOI: 10.1016/j.jep.2007.03.013. View

13.

Etemad-Moghadam S, Fouladdel S, Azizi E, Alaeddini M . In vitro study on the effect of doxorubicin on the proliferation markers MCM3 and Ki-67. J BUON. 2013; 18(4):1062-8. View

14.

Nelo-Bazan M, Latorre P, Bolado-Carrancio A, Perez-Campo F, Echenique-Robba P, Rodriguez-Rey J . Early growth response 1 (EGR-1) is a transcriptional regulator of mitochondrial carrier homolog 1 (MTCH 1)/presenilin 1-associated protein (PSAP). Gene. 2015; 578(1):52-62. DOI: 10.1016/j.gene.2015.12.014. View

15.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View

16.

Lim W, Kang C . Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell lung cancer cells. Anim Cells Syst (Seoul). 2020; 24(2):79-83. PMC: 7241542. DOI: 10.1080/19768354.2020.1748108. View

17.

Fang X, Jiang H, Zhu Y, Zhang L, Fan Q, Tian Y . Doxorubicin induces drug resistance and expression of the novel CD44st via NF-κB in human breast cancer MCF-7 cells. Oncol Rep. 2014; 31(6):2735-42. DOI: 10.3892/or.2014.3131. View

18.

Plumb J . Cell sensitivity assays: the MTT assay. Methods Mol Med. 2003; 88:165-9. DOI: 10.1385/1-59259-406-9:165. View

19.

Lamarca V, Sanz-Clemente A, Perez-Pe R, Martinez-Lorenzo M, Halaihel N, Muniesa P . Two isoforms of PSAP/MTCH1 share two proapoptotic domains and multiple internal signals for import into the mitochondrial outer membrane. Am J Physiol Cell Physiol. 2007; 293(4):C1347-61. DOI: 10.1152/ajpcell.00431.2006. View

20.

Lytovchenko O, Kunji E . Expression and putative role of mitochondrial transport proteins in cancer. Biochim Biophys Acta Bioenerg. 2017; 1858(8):641-654. DOI: 10.1016/j.bbabio.2017.03.006. View